Skip to content

Premium Pharma OÜ

Registry code (registrikood) 14928540Private limited company (Osaühing)VAT EE102242083Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€7.1M
▲ 6.9% vs 2024
Profit before tax (2025)
€20k
Employees, FTE (2025)
22
State taxes paid, last 4 quarters
€479k

Revenue, profit and employees, 2020–2025

€3.4M2020€5.0M2021€5.4M2022€6.0M2023€6.6M2024€7.1M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2020€3,361,803€21,967€23,606€23,60619
2021€4,990,221€40,237€43,360€66,96625
2022€5,443,713€36,840€39,972€106,93819
2023€5,979,527-€100,924-€97,786€9,15223
2024€6,599,547-€9,569-€4,874€4,27723
2025€7,054,505€16,673€20,187€24,46422

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2020€176,965€827,065€803,459—€23,606
2021€370,013€1,043,616€976,650—€66,966
2022€446,227€1,254,567€1,147,629—€106,938
2023€258,797€1,184,971€1,175,819—€9,152
2024€164,789€1,290,564€1,286,287—€4,277
2025€354,831€1,392,169€1,367,705—€24,464

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€87,607€68,520€1,465,42023
2022 Q2€77,181€63,077€1,462,67025
2022 Q3€83,469€70,877€1,435,31120
2022 Q4€77,075€60,964€1,501,02724
2023 Q1€85,874€77,362€1,581,81527
2023 Q2€90,485€76,700€1,657,44030
2023 Q3€101,902€90,566€1,644,97732
2023 Q4€99,580€83,067€1,718,08632
2024 Q1€108,335€91,693€1,706,05831
2024 Q2€102,014€85,917€1,742,14133
2024 Q3€99,252€90,192€1,775,21130
2024 Q4€101,795€91,622€1,833,77730
2025 Q1€144,876€98,281€1,914,25929
2025 Q2€114,165€93,450€1,941,18728
2025 Q3€109,210€96,827€1,867,35429
2025 Q4€115,107€93,252€1,990,95830
2026 Q1€135,287€91,450€1,893,85631
2026 Q2€109,442€86,275€1,824,31025
2026 Q3€119,520€92,759€1,641,35123

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), Premium Pharma OÜ reported revenue of €7,054,505.

The company closed the 2025 financial year with a net profit of €20,187.

Revenue increased by 6.9% from €6,599,547 in 2024 to €7,054,505 in 2025.

Revenue grew at a compound annual rate of 16.0% between 2020 and 2025.

Equity accounted for 1.8% of total assets of €1,392,169 at the end of the 2025 reporting period.

With 22 full-time-equivalent employees in 2025, revenue per employee was €320,659.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, Premium Pharma OÜ reported €7,350,475 in turnover.

EMTA recorded 23 employees for the quarter ending Q3 2026, compared with 22 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.